Hydrodistention and anti-cholinergics are usefull for bladder contracture caused by intravesical BCG therapy: A case report
İntravezikal immünoterapi yüzeyel mesane tümörlerinde tamamlayıcı bir tedavidir. Yüzeyel mesane tümörlerinin tedavisinde intravezikal BCG kullanımı çok etkin olmakla birlikte, toksisite riski gözönünde bulundurulmalıdır. İntravezikal BCG tedavisi hastaların çoğunda iyi tolere edilir ancak tedaviye bağlı yan etkiler görülebilir. Mesane kontraktürü bu uygulamaya bağlı olarak gelişen ciddi komplikasyonlardan biridir. Yüksek grade pT1 yüzeyel mesane tümörü olan ve intravezikal BCG tedavisi uygulanan ancak mesane kontraktürü gelişen olgumuzu sunuyoruz. İntravezikal BCG uygulama sonrası hastamızda gelişen mesane kontraktürünün tedavisinde antikolinerjikler ve hidrodistansiyon etkili olmuştur.
İntravezikal BCG tedavisine bağlı mesane kontraktüründe hidrodistansiyon ve antikolinerjikler faydalıdır: Bir olgu sunumu
Intravesical immunotherapy is a complementary treatment in patients with superficial urothelial carcinoma of the bladder. Although intravesical instillation of Bacillus Calmette-Guérin (BCG) is very effective in patients with superficial bladder cancer, it should be kept in mind that it has a risk of toxicity. The majority of patients tolerate BCG instillations well but adverse effects may occur. Bladder contracture is a serious local complication of this application. We report a case of high grade pT1 superficial bladder cancer treated successfully with intravesical BCG and developed bladder contracture after the therapy. The patient was managed successfully with anticholinergics and hydrodistention.
___
- 1. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou Redorta J. European Association of Urology (EAU): EAU guidelines on nonmuscle invasive urothelial carcinoma of the bladder. Eur Urol 2008;54:303-14.
- 2. Demkow T, Alter A, Wiechno P. Intravesical bacillus Calmette Guérin therapy for T1 superficial bladder cancer. Urol Int 2008;80(1):74-9.
- 3. Sylvester RJ, van der Meijden APM, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002;168:1964-70.
- 4. Böhle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus Mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003;169:90-5.
- 5. Sylvester RJ, van der Meijden APM, Witjes JA, Kurth K. Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 2005;174:86-91.
- 6. Koya MP, Simon MA, Soloway MS. Complications of intravesical therapy for urothelial cancer of the bladder. J Urol 2006;175:2004-10.
- 7. Shelley MD, Kynaston H, Court J, Wilt TJ, Coles B, Burgon K, et al. A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int 2001;88(3):209-16.
- 8. Lamm DL, van der Meijden PM, Morales A, Brosman SA, Catalona WJ, Herr HW, et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol 1992;147:596-600.
- 9. Grossman HB. Bladder contracture following intravesical BCG immunotherapy. Urology 1993;41:353-5.
- 10. Hameed A, Sezian N, Thwaini A. Bladder contracture: review for intravesical bacillus Calmette-Guerin complication. Can J Urol 2007;14:3745-9.